Back to results
US 6,844,000 B2Granted
Use of Parapox B2L protein to treat cancer and modify immune responses
AssigneeBayer Pharmaceuticals Corporation
InventorsDelanie Cassell, Jeffrey S. Tepper, Isa Samuels, Nathalie Dubois-Stringfellow
Life of this patent
Estimating the term…
Abstract
A purified Parapoxvirus ovis envelope protein termed “B2L” can be used as a monotherapeutic agent. B2L protein also can be used in screening methods to identify potential therapeutic agents for modulating a subject's immune response to the B2L protein.
Claims4
A method of treating a patient having a cell proliferative disorder, comprising the step of:
- administering to the patient an effective amount of a purified and isolated B2L viral envelope protein of a Parapox virus, whereby symptoms of the patient's cell proliferative disorder are ameliorated.
A method of enhancing an immune response to endogenous antigens associated with a cell proliferative disorder, comprising the step of:
- administering to a subject in need thereof an effective amount of a purified and isolated B2L viral envelope protein of a Parapox virus, whereby the B2L viral envelope protein enhances the immune response to the endogenous antigens.
Dependencies are inferred from the claim text.